Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by the ability of the immobilized protein to support the adhesion of the L Cells mouse fibroblast cell line. The ED 50 for this effect is 0.4-2.4 μg/mL
Source
Human embryonic kidney cell, HEK293-derived
Human CEACAM-19
(Ala33-Gly157)
Accession # Q7Z692-1IEGRMD Human IgG1
(Pro100-Lys330)N-terminus C-terminus Accession #
N-terminal Sequence
AnalysisAla33
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
40 kDa
SDS-PAGE
42-56 kDa, reducing conditions
9397-CM |
| |
Formulation Lyophilized from a 0.2 μm filtered solution in PBS. | ||
Reconstitution Reconstitute at 500 μg/mL in PBS. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Data Images
Bioactivity
| Immobilized Recombinant Human CEACAM-19 (Catalog # 9397-CM)enhances L Cells mouse fibroblasts adhesion. The ED50 for this effect is 0.4-2.4 μg/mL. |
Background: CEACAM-19
Carcinoembryonic antigen-related cell adhesion molecule-19 (CEACAM-19), also known as CEA-like gene 1 (CEAL1), is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-19 consists of a 125 amino acid (aa) extracellular domain, a 21 aa helical transmembrane domain, and a 122 aa cytoplasmic domain (1,2). The extracellular domain contains an Ig-like domain as well as a glycosylation site, while the cytoplasmic domain is predicted to contain at least one immunoreceptor tyrosine-based activation motif (ITAM) (3,4). The extracellular domain of human CEACAM-19 shows 71%, 72%, and 78% aa identity to mouse, rat, and bovine CEACAM-19. The CEACAM family of proteins are involved in numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, cell growth, recognition and differentiation, angiogenesis, and apoptosis (5,6). CEACAM-19 expression has been identified in a wide range of tissues including prostate, uterus, fetal brain, mammary and adrenal glands, skeletal muscle, small intestine, and kidney (1). Human CEACAM-19 has been found to be overexpressed in BT-474, BT20, and T47D breast cancer cell lines as well as LNCaP prostate cancer cells, suggesting a role in tumor progression and metastasis (1,3, 7). The overexpression in breast cancer patients is associated with poor prognosis (7).
References:
Schorilas, A. et al. (2003) Gene 310:79.
Estiar, M. et al. (2016) Clin Exp Med doi:10.1007/s10238-016-0442-1.
Beauchemin, N. and Arabzadeh, A. (2013) Cancer Metastasis Rev 32 (3-4):643.
Kuespert, K. et al. (2006) Curr Opin Cell Biol 18:565.
Obrink, B. (1997) Curr Opin Cell Biol 9:616.
Horst, AK. and Wagener, C. (2004) Handb Exp Pharmacol 283.
Michaelidou, K. et al. (2013) Int J Oncol 42:1770.
Long Name:
Carcinoembryonic Antigen-related Cell Adhesion Molecule 19
Entrez Gene IDs:
56971 (Human); 319930 (Mouse); 680640 (Rat)
Alternate Names:
carcinoembryonic antigen-related cell adhesion molecule 19; CEACAM19; CEACAM-19; CEAL1
